FDAsafety guidance83% confidence
January - March 2026 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event Monitoring System (AEMS)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (breast cancer) as Merck.
Regulatory Analysis
January - March 2026 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event Monitoring System (AEMS)
Supporting Context
- Therapeutic area
- Oncology · Triple-Negative Breast Cancer
- Sub-indication
- Breast Cancer
Related signal: Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab